Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2026
Health Canada authorizes Lunsumio (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies
8 June 2026 - Roche Canada is pleased to announce that Health Canada has granted market authorisations for Lunsumio (mosunetuzumab ...
Posted by Michael Wonder on 05 Jun 2026
Kashiv BioSciences announces validation and acceptance of market authorisation application by Health Canada for ADL-018, a proposed biosimilar to Xolair (omalizumab)
4 June 2026 - Kashiv BioSciences today announced that Health Canada has validated and accepted the marketing authorisation application for ADL-018, ...
Posted by Michael Wonder on 04 Jun 2026
Why Canada has generic Ozempic, and the US doesn't
3 June 2026 - Elizabeth Doran has been taking GLP-1 medications for nearly a year for weight loss to help ...
Posted by Michael Wonder on 03 Jun 2026
Celltrion files for approval of Cosentyx biosimilar, CT-P55, in Canada
1 June 2026 - Celltrion announced on Monday that it has submitted a regulatory application to Health Canada for CT-P55, ...
Posted by Michael Wonder on 02 Jun 2026
Loargys (pegzilarginase for injection) approved in Canada for the treatment of arginase 1 deficiency
1 June 2026 - Immedica announces that Health Canada has granted a Notice of Compliance on 29 May 2026 for Loargys ...
Posted by Michael Wonder on 27 May 2026
Apotex expands ophthalmic portfolio with Health Canada approval of Iheezo
26 May 2026 - Apotex today announced that Health Canada has approved Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical ...
Posted by Michael Wonder on 22 May 2026
Vertex announces new drug submission for suzetrigine has been accepted for review by Health Canada for the treatment of moderate to severe acute pain in adults
21 May 2026 - Vertex Pharmaceuticals today announced that Health Canada has accepted for review a new drug submission for ...
Posted by Michael Wonder on 20 May 2026
BioSyent announces Health Canada approval of Thyconvi (levothyroxine oral solution)
19 May 2026 - BioSyent announces that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral ...
Posted by Michael Wonder on 15 May 2026
Apotex launches Apo‑Semaglutide Injection, a generic equivalent of Ozempic, in Canada
14 May 2026 - Apotex today announced the commercial launch of Apo‑Semaglutide Injection – a generic equivalent of Ozempic. ...
Posted by Michael Wonder on 06 May 2026
Healyth Canada authorised Lilly's Kisunla (donanemab), a new treatment for early Alzheimer's disease
4 May 2026 - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health Canada's ...
Posted by Michael Wonder on 03 May 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic
1 May 2026 - Apotex today announced that Health Canada has approved Apo‑Semaglutide Injection, a generic equivalent of Ozempic (semaglutide injection). ...
Posted by Michael Wonder on 03 May 2026
Novartis receives Health Canada approval for Fabhalta oral treatment for adults with C3G
1 May 2026 - Novartis Pharmaceuticals Canada announced today that Health Canada has granted a Notice of Compliance for Fabhalta (iptacopan ...
Posted by Michael Wonder on 29 Apr 2026
Canada becomes the first G7 country to approve a generic version of semaglutide
28 April 2026 - Today, Health Canada authorised a generic semaglutide injection. This is the first generic semaglutide authorised by Health ...
Posted by Michael Wonder on 22 Apr 2026
Biocon receives Health Canada approval of Bosaya (denosumab) and Vevzuo (denosumab), biosimilars to Prolia and Xgeva
21 April 2026 - Biocon is pleased to announce that Health Canada has granted a Notice of Compliance for Bosaya (denosumab), ...
Posted by Michael Wonder on 18 Apr 2026
Bracco receives Health Canada approval for Vueway injection (gadopiclenol), advancing lower dose MRI contrast imaging
17 April 2026 - Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance ...